Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | KMO | O15229 | 6/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12492145 | 0.84 | CYP3A4 (0.52) | NPY5RSLC6A2SLC6A4SLC6A3KMO | |
| SCHEMBL25326508 | 0.84 | KMO (0.49) | NPY5RSLC6A2SLC6A4SLC6A3KMO | |
| SCHEMBL28629827 | 0.83 | NPY5R (0.63) | NPY5RSLC6A2SLC6A4SLC6A3KMO | |
| SCHEMBL29712850 | 0.83 | NPY5R (0.63) | NPY5RSLC6A2SLC6A4SLC6A3KMO | |
| SCHEMBL28638540 | 0.80 | NPY5R (1.00) | NPY5RADORA2A | |
| SCHEMBL11541937 | 0.79 | CYP2D6 (0.60) | NPY5RPIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL16995118 | 0.79 | PIM2 (0.52) | NPY5RKMOPIM1PIM2ALDH1A1 | |
| SCHEMBL28185286 | 0.79 | MKNK1 (0.47) | NPY5RKMOPIK3CDPIK3CAPIK3CB | |
| SCHEMBL10353034 | 0.78 | RAB9A (0.60) | NPY5RSLC6A2SLC6A4SLC6A3PIK3CD | |
| SCHEMBL30112767 | 0.76 | HSD11B1 (0.48) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820318-A | P-type organic positive electrode material and preparation method and application thereof | 上海电力大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-117402494-A | Complex high-strength polyarylene sulfide based composite material and preparation and application thereof | 新凝合科技(成都)有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-115895441-B | Electrostatic spraying coating for glove mold and preparation method thereof | 南通源创设备科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-111057004-B | N-o-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof | 宁波大学 | 2023-10-31 | — | — | CN | disclosed |
| CN-116924995-A | Method for synthesizing benzimidazole compound by catalyzing L-phenylalanine | 宁夏师范学院 | 2023-10-24 | — | — | CN | disclosed |
| CN-114989094-B | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-114890952-B | Preparation method of 5-halogeno-2-aminobenzoazacyclic compound | 重庆医科大学 | 2023-06-06 | — | — | CN | disclosed |
| US-20170299530-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS, AND METHOD FOR QUANTITATING SACCHARIDE | ACADEMIA SINICA (TW) | 2017-10-19 | — | — | US | disclosed |
| US-20150168415-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS | ACADEMIA SINICA (TW) | 2015-06-18 | — | — | US | disclosed |
| EP-0927170-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-10-08 | — | — | EP | disclosed |
| US-5981520-A | USEFUL FOR TREATING ASTHMA, BRONCHOSPASM, ALLERGIES, ANXIETY, COUGHING OR PAIN | SCHERING CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0927170-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-07-07 | — | — | EP | disclosed |
| US-5892039-A | Piperazino derivatives as neurokinin antagonists | SCHERING CORPORATION (US) | 1999-04-06 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1998008826-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0204172-B1 | PHENYLPYRAZINE DERIVATIVES, PROCESSES FOR PREPARING THEM, PHARMACEUTICAL COMPOSITION AND USE | SUNTORY LIMITED (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4755514-A | Phenylpyrazine derivatives and thrombolytic agent | SUNTORY LIMITED (JP) | 1988-07-05 | — | — | US | disclosed |
| EP-0204172-A2 | Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use | SUNTORY LIMITED (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150168415-A1 | COMPOUNDS AND METHODS FOR ANALYSIS AND SYNTHESIS OF SACCHARIDE COMPOUNDS | MPI, GPI, FUT6 | NPY5R 1977/4885SLC6A2 2652/4885SLC6A4 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.